Current Problems in Cancer
Volume 29, Issue 1 , Pages 8-32 , January 2005

Novel apoptosis inducing agents in cancer therapy

  • Monica Mita, MD

      Affiliations

    • Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas, USA
    • ,
  • Anthony W. Tolcher, MD

      Affiliations

    • Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas, USA
    • Corresponding Author InformationAddress correspondence to Dr. Anthoney W. Tolcher, 7979 Wurzbach Suite 414, San Antonio, TX 78229, USA

References 

  1. Thornberry NA , Lazebnik Y . Caspases (enemies within) . Science . 1998;281:1312–1316
  2. Igney FH , Krammer PH . Death and anti-death (tumour resistance to apoptosis) . Nat Rev Cancer . 2002;2:277–288
  3. Hanahan D , Weinberg RA . The hallmarks of cancer . Cell . 2000;100:57–70
  4. Hickman JA . Apoptosis and chemotherapy resistance . Eur J Cancer . 1996;32A:921–926
  5. Adams JM , Cory S . The Bcl-2 protein family (arbiters of cell survival) . Science . 1998;281:1322–1326
  6. Reed JC , Miyashita T , Takayama S , et al.  BCL-2 family proteins (regulators of cell death involved in the pathogenesis of cancer and resistance to therapy) . J Cell Biochem . 1996;60:23–32
  7. Chittenden T . BH3 domains (intracellular death-ligands critical for initiating apoptosis) . Cancer Cell . 2002;2:165–166
  8. Hockenbery DM . bcl-2 in cancer, development and apoptosis . J Cell Sci Suppl . 1994;18:51–55
  9. Chittenden T , Flemington C , Houghton AB , et al.  A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions . EMBO J . 1995;14:5589–5596
  10. Tong Y , Yang Q , Vater C , et al.  The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain . Mol Cancer Ther . 2001;1:95–102
  11. Hainaut P . The tumor suppressor protein p53 (a receptor to genotoxic stress that controls cell growth and survival) . Curr Opin Oncol . 1995;7:76–82
  12. Jurgensmeier JM , Xie Z , Deveraux Q , et al.  Bax directly induces release of cytochrome c from isolated mitochondria . Proc Natl Acad Sci U S A . 1998;95:4997–5002
  13. Narita M , Shimizu S , Ito T , et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria . Proc Natl Acad Sci U S A . 1998;95:14681–14686
  14. Pan G , O’Rourke K , Dixit VM . Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex . J Biol Chem . 1998;273:5841–5845
  15. Hausmann G , O’Reilly LA , van Driel R , et al.  Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L) . J Cell Biol . 2000;149:623–634
  16. Newmeyer DD , Bossy-Wetzel E , Kluck RM , et al.  Bcl-xL does not inhibit the function of Apaf-1 . Cell Death Differ . 2000;7:402–407
  17. Danial NN , Korsmeyer SJ . Cell death (critical control points) . Cell . 2004;116:205–219
  18. Tsujimoto Y , Finger LR , Yunis J , et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation . Science . 1984;226:1097–1099
  19. Tsujimoto Y , Ikegaki N , Croce CM . Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma . Oncogene . 1987;2:3–7
  20. McDonnell TJ , Deane N , Platt FM , et al.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation . Cell . 1989;57:79–88
  21. Gascoyne RD , Adomat SA , Krajewski S , et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma . Blood . 1997;90:244–251
  22. McDonnell TJ , Troncoso P , Brisbay SM , et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer . Cancer Res . 1992;52:6940–6944
  23. Krajewska M , Krajewski S , Epstein JI , et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers . Am J Pathol . 1996;148:1567–1576
  24. Krajewski S , Thor AD , Edgerton SM , et al.  Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers . Clin Cancer Res . 1997;3:199–208
  25. Cox G , Louise Jones J , Andi A , et al.  Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer . Lung Cancer . 2001;34:417–426
  26. Mueller J , Mueller E , Hoepner I , et al.  Expression of bcl-2 and p53 in de novo and ex-adenoma colon carcinoma (a comparative immunohistochemical study) . J Pathol . 1996;180:259–265
  27. Apakama I , Robinson MC , Walter NM , et al.  bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer . Br J Cancer . 1996;74:1258–1262
  28. Miyashita T , Reed JC . bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs . Cancer Res . 1992;52:5407–5411
  29. Fisher TC , Milner AE , Gregory CD , et al.  bcl-2 modulation of apoptosis induced by anticancer drugs (resistance to thymidylate stress is independent of classical resistance pathways) . Cancer Res . 1993;53:3321–3326
  30. Ohmori T , Podack ER , Nishio K , et al.  Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2 . Biochem Biophys Res Commun . 1993;192:30–36
  31. Walton MI , Whysong D , O’Connor PM , et al.  Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis . Cancer Res . 1993;53:1853–1861
  32. Raffo AJ , Perlman H , Chen MW , et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo . Cancer Res . 1995;55:4438–4445
  33. Kyprianou N , King ED , Bradbury D , et al.  bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells . Int J Cancer . 1997;70:341–348
  34. Kaufmann SH , Vaux DL . Alterations in the apoptotic machinery and their potential role in anticancer drug resistance . Oncogene . 2003;22:7414–7430
  35. Dorai T , Goluboff ET , Olsson CA , et al.  Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents . Anticancer Res . 1997;17:3307–3312
  36. Campos L , Sabido O , Rouault JP , et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells . Blood . 1994;84:595–600
  37. Paterson BM , Roberts BE , Kuff EL . Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation . Proc Natl Acad Sci U S A . 1977;74:4370–4374
  38. Zamecnik PC , Goodchild J , Taguchi Y , et al.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA . Proc Natl Acad Sci U S A . 1986;83:4143–4146
  39. Stephenson ML , Zamecnik PC . Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide . Proc Natl Acad Sci U S A . 1978;75:285–288
  40. Crooke ST . Molecular mechanisms of antisense drugs (RNase H) . Antisense Nucleic Acid Drug Dev . 1998;8:133–134
  41. Crooke ST . Molecular mechanisms of action of antisense drugs . Biochim Biophys Acta . 1999;1489:31–44
  42. Ziegler A , Luedke GH , Fabbro D , et al.  Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence . J Natl Cancer Inst . 1997;89:1027–1036
  43. Jansen B , Schlagbauer-Wadl H , Brown BD , et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice . Nat Med . 1998;4:232–234
  44. Gleave M , Tolcher A , Miyake H , et al.  Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model . Clin Cancer Res . 1999;5:2891–2898
  45. Benimetskaya L , Miller P , Benimetsky S , et al.  Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides (relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells) . Mol Pharmacol . 2001;60:1296–1307
  46. Wacheck V , Heere-Ress E , Halaschek-Wiener J , et al.  Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model . J Mol Med . 2001;79:587–593
  47. Klasa RJ , Bally MB , Ng R , et al.  Eradication of human non-Hodgkin’s lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide . Clin Cancer Res . 2000;6:2492–2500
  48. Affar EB , Germain M , Winstall E , et al.  Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis . J Biol Chem . 2001;276:2935–2942
  49. Miayake H , Tolcher A , Gleave ME . Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides . J Natl Cancer Inst . 2000;92:34–41
  50. Koty PP , Zhang H , Levitt ML . Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines . Lung Cancer . 1999;23:115–127
  51. Lacy J , Loomis R . Bcl-2 antisense (G3139, oblimersen) enhances the in vitro and in vivo responses of EBV-associated lymphoproliferative disease to rituximab . Proc Annu Meet Am Assoc Cancer Res . 2002;43:575; [abstr 2853]
  52. Lopes  , Mayer LD . Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts . Cancer Chemother Pharmacol . 2002;49:57–68
  53. Webb A , Cunningham D , Cotter F , et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma . Lancet . 1997;349:1137–1141
  54. Waters JS , Webb A , Cunningham D , et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma . J Clin Oncol . 2000;18:1812–1823
  55. Morris MJ , Tong WP , Cordon-Cardo C , et al.  Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer . Clin Cancer Res . 2002;8:679–683
  56. Raynaud FI , Orr RM , Goddard PM , et al.  Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice . J Pharmacol Exp Ther . 1997;281:420–427
  57. O’Brien S , Giles F , Rai K , et al.  Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia . Blood . 2001;98:772a
  58. Tsujimoto Y , Cossman J , Jaffe E , et al.  Involvement of the bcl-2 gene in human follicular lymphoma . Science . 1985;228:1440–1443
  59. Pepper C , Thomas A , Hoy T , et al.  Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia . Br J Haematol . 1999;107:611–615
  60. Yamamura K , Kamada S , Ito S , et al.  Accelerated disappearance of melanocytes in bcl-2-deficient mice . Cancer Res . 1996;56:3546–3550
  61. Selzer E , Schlagbauer-Wadl H , Okamoto I , et al.  Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines . Melanoma Res . 1998;8:197–203
  62. Grover R , Wilson GD . Bcl-2 expression in malignant melanoma and its prognostic significance . Eur J Surg Oncol . 1996;22:347–349
  63. Chapman PB , Einhorn LH , Meyers ML , et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma . J Clin Oncol . 1999;17:2745–2751
  64. Ochoa L , Kuhn J , Salinas R , et al.  A Phase I pharmacokinetic and biologic correlative study of G3139 and irinotecan in patients with metastatic colorectal cancer . Proc Am Soc Clin Oncol . 2001;20:75a
  65. Banks DP , Plescia J , Altieri DC , et al.  Survivin does not inhibit caspase-3 activity . [comment] Blood . 2000;96:4002–4003
  66. Marcucci G , Byrd JC , Dai G , et al.  Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense nucleotide, in combination with chemotherapy in refractory and relapsed acute leukemia . Blood . 2003;101(2):425–432
  67. Chen HX , Marshall JL , Trocky N , et al.  A phase I study of Bcl-2 antisense G3139 and weekly docetaxel in patients with advanced breast cancer and other solid tumors . Proc Am Soc Clin Oncol . 2000;19:178; [abstr 692]
  68. Rudin CM , Otterson GA , Mauer AM , et al.  A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer . Ann Oncol . 2002;13:539–545
  69. Jansen B , Wacheck V , Heere-Ress E , et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy . Lancet . 2000;356:1728–1733
  70. Millward MJ , Bedikian AY , Conry RM , et al.  Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma . Proc Am Soc Clin Oncol . 2004;23:708; (abstr 7505)
  71. Hay BA . Understanding IAP function and regulation (a view from Drosophila) . Cell Death Differ . 2000;7:1045–1056
  72. Deveraux QL , Roy N , Stennicke HR , et al.  IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases . EMBO J . 1998;17:2215–2223
  73. Salvesen GS , Duckett CS . IAP proteins (blocking the road to death’s door) . Nat Rev Mol Cell Biol . 2002;3:401–410
  74. Liston P , Wai Gin Fong , Korneluk RG . The inhibitors of apoptosis (there is more to life than bcl-2) . Oncogene . 2003;22:8568–8580
  75. Devereaux QL , Takehashi R , Salvessen GS , Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases . Nature . 1997;388(6639):300–304
  76. Ambrosini G , Adida C , Altieri DC . A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma . Nat Med . 1997;3:917–921
  77. Gazzaniga P , Gradilone A , Giuliani L , et al.  Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer . Ann Oncol . 2003;14:85–90
  78. Ka H , Hunt JS . Temporal and spatial patterns of expression of inhibitors of apoptosis in human placentas . Am J Pathol . 2003;163:413–422
  79. Monzo M , Rosell R , Felip E , et al.  A novel anti-apoptosis gene (Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers) . J Clin Oncol . 1999;17:2100–2104
  80. Tanaka K , Iwamoto S , Gon G , et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas . Clin Cancer Res . 2000;6:127–134
  81. Satoh K , Kaneko K , Hirota M , et al.  Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer . Pancreas . 2001;23:251–258
  82. Kawasaki H , Altieri DC , Lu CD , et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer . Cancer Res . 1998;58:5071–5074
  83. Chakravarti A , Noll E , Black PM , et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas . J Clin Oncol . 2002;20:1063–1068
  84. Grossman D , McNiff JM , Li F , et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma . [erratum appears in J Invest Dermatol 2000;114:609] J Invest Dermatol . 1999;113:1076–1081
  85. Kappler M , Bache M , Bartel F , et al.  Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53 . Cancer Gene Ther . 2004;11:186–193
  86. Islam A , Kageyama H , Takada N , et al.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma . Oncogene . 2000;19:617–623
  87. Tamm I , Wang Y , Sausville E , et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs . Cancer Res . 1998;58:5315–5320
  88. Speliotes EK , Uren A , Vaux D , et al.  The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone . Mol Cell . 2000;6:211–223
  89. Li F , Ambrosini G , Chu EY , et al.  Control of apoptosis and mitotic spindle checkpoint by survivin . Nature . 1998;396:580–584
  90. Giodini A , Kallio MJ , Wall NR , et al.  Regulation of microtubule stability and mitotic progression by survivin . Cancer Res . 2002;62:2462–2467
  91. Altieri DC . Survivin, versatile modulation of cell division and apoptosis in cancer . Oncogene . 2003;22:8581–8589
  92. Castedo M , Perfettini JL , Roumier T , et al.  Cell death by mitotic catastrophe (a molecular definition) . Oncogene . 2004;23:2825–2837
  93. Hattori M , Sakamoto H , Satoh K , et al.  DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes . Cancer Lett . 2001;169:155–164
  94. Van Antwerp DJ , Martin SJ , Kafri T , et al.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB . [see comment] Science . 1996;274:787–789
  95. Lu CD , Altieri DC , Tanigawa N . Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas . Cancer Res . 1998;58:1808–1812
  96. Tran J , Master Z , Yu JL , et al.  A role for survivin in chemoresistance of endothelial cells mediated by VEGF . Proc Natl Acad Sci U S A . 2002;99:4349–4354
  97. Adida C , Recher C , Raffoux E , et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia . Br J Haematol . 2000;111:196–203
  98. Adida C , Berrebi D , Peuchmaur M , et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma . Lancet . 1998;351:882–883
  99. Davidovich IA , Levenson AS , Levenson Chernokhvostov VV . Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance . Cancer Lett . 2004;211:189–197
  100. Notarbartolo M , Cervello M , Poma P , et al.  Expression of the IAPs in multidrug resistant tumor cells . Oncol Reports . 2004;11:133–136
  101. Wang L , Zhang GM , Feng ZH . Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line . Acta Pharmacol Sinica . 2003;24:1235–1240
  102. Zaffaroni N , Pennati M , Colella G , et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer . Cell Mol Life Sci . 2002;59:1406–1412
  103. Andersen MH , Thor SP . Survivin-a universal tumor antigen . Histol Histopathol . 2002;17:669–675
  104. Grossman D , McNiff JM , Li F , et al.  Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line . Lab Invest . 1999;79:1121–1126
  105. Ling X , Li F . Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology . Biotechniques . 2004;36:450–454
  106. Pitti RM , Marsters SA , Lawrence DA , et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer . Nature . 1998;396:699–703
  107. Marsters SA , Sheridan JP , Donahue CJ , et al.  Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B . Curr Biol . 1996;6:1669–1676
  108. Marsters SA , Sheridan JP , Pitti RM , et al.  Identification of a ligand for the death-domain-containing receptor Apo3 . Curr Biol . 1998;8:525–528
  109. Ashkenazi A , Dixit VM . Death receptors (signaling and modulation) . Science . 1998;281:1305–1308
  110. Suliman A , Lam A , Datta R , et al.  Intracellular mechanisms of TRAIL (apoptosis through mitochondrial-dependent and -independent pathways) . Oncogene . 2001;20:2122–2133
  111. Kischkel FC , Lawrence DA , Tinel A , et al.  Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 . J Biol Chem . 2001;276:46639–46646
  112. Bodmer JL , Holler N , Reynard S , et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 . Nat Cell Biol . 2000;2:241–243
  113. Kaufmann M , Bozic D , Briand C , et al.  Identification of a basic surface area of the FADD death effector domain critical for apoptotic signaling . FEBS Lett . 2002;527:250–254
  114. Muhlenbeck F , Schneider P , Bodmer JL , et al.  The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation . J Biol Chem . 2000;275:32208–32213
  115. Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily . Nat Rev Cancer . 2002;2:420–430
  116. Hymowitz SG , O’Connell MP , Ultsch MH , et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL . Biochemistry . 2000;39:633–640
  117. Hymowitz SG , Christinger HW , Fuh G , et al.  Triggering cell death (the crystal structure of Apo2L/TRAIL in a complex with death receptor 5) . Mol Cell . 1999;4:563–571
  118. Bodmer JL , Holler N , Reynard S , et al.  Trail receptor-2 signals apoptosis through FADD and caspase 8 . Nat Cell Biol . 2003;2(4):241–243
  119. Ashkenazi A , Pai RC , Fong S , et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand . J Clin Invest . 1999;104:155–162
  120. Walczak H , Miller RE , Ariail K , et al.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo . Nat Med . 1999;5:157–163
  121. Jo M , Kim TH , Seol DW , et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand . Nat Med . 2000;6:564–567
  122. Tolcher AW , Mita M , Patnaik A , et al.  A phase I and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors . Proc Am Soc Clin Oncol . 2004;23:210; [abstr 3060]
  123. Le LH , Hirte HW , Hotte SJ , et al.  Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkins lymphoma . Proc Am Soc Oncol . 2004;22:171s
  124. Aggarwal BB , Bhardwaj U , Takada Y . Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors . Vitam Horm . 2004;67:453–483
  125. Fulda S , Meyer E , Debatin KM . Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression . Oncogene . 2002;21:2283–2294
  126. Munshi A , Pappas G , Honda T , et al.  TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2 . Oncogene . 2001;20:3757–3765
  127. Hinz S , Trauzold A , Boenicke L , et al.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis . Oncogene . 2000;19:5477–5486

PII: S0147-0272(04)00076-5

doi: 10.1016/j.currproblcancer.2004.11.001

Current Problems in Cancer
Volume 29, Issue 1 , Pages 8-32 , January 2005

Article Tools

* Image Usage & Resolution